Comprehensive report on #MET exon 14 mutant NSCLC Lung Cancer Journal led by Dr. Jennifer Marks, MD. Over 700 cases included with striking heterogeneity in co-mutations, amplifications, makeup of TME. Also, significant difference in outcomes by histology. lungcancerjournal.info/article/S0169-…

Dr. Alissa Cooper, MD will help us catch up on all of the major updates with antibody drug conjugates (ADCs) in NSCLC at #DCLung24. Join us Saturday, October 19th in downtown Washington, DC for this IASLC endorsed, one-day #CME #MOC #ANCC meeting! medstarhealth.org/dclung24

Going to #WCLC24? Join the Meet the Expert session on Monday, September 9th at 7:30am in room 33ABC for the "Do You Know Your Targets" Quiz show where Dr. Natasha Leighl will go head to head against Dr. Ben Solomon! I'll host and we'll take a few crowd volunteers to play along!

Real world data from Italy on #MET exon 14 mutations in NSCLC ESMO Open. In 146 pts with #METex14 NSCLC, 38% given capmatinib and 23% tepotinib. RR to MET inhibitors was 46% as 1L therapy, 33% in later lines. mPFS 6.6m, mOS 10.7m, intracranial RR 41%. esmoopen.com/article/S2059-…

We are pleased to announce that our journal now accepts *Trial in Progress (TiP) papers*, including ongoing phase II and III trials registered with NCI's Clinical Trials Reporting Program. All submission guidelines are available here 🔗sciencedirect.com/journal/lung-c…

Looking forward to #WCLC24 - join us for lunch on Monday September 9th, 12:15pm, Ballroom 20A (Upper Level) - where we'll discuss updates in ADCs for lung cancer in this PeerView #CME with Drs. Melissa L. Johnson d.planchard and me! Hope to see you there!

They say everything is larger in Texas Well- i can now confirm it from two different angles 1. Steaks 2. How much fun one can have at a lung cancer conference Stephen V Liu, MD TLC Conference #TexasLung #TLC

While amylase & lipase elevation often seen in trials of targeted agents, actual clinical pancreatitis is uncommon. In this retrospective report Clinical Lung Cancer from Drs. Meyer May-Lucie Mihaela Aldea and team, incidence of clinical pancreatitis was .08%! clinical-lung-cancer.com/article/S1525-…

Dr. Ticiana Batista (Leal) joins #DCLung24 with an overview of TTFields and their use in mesothelioma and in NSCLC. Some important updated data to review. Join us Saturday, October 19th in downtown Washington, DC for this IASLC endorsed, one-day #CME meeting! medstarhealth.org/dclung24

Join us at #WCLC24 on Monday, September 9th, 7:30am, room 33ABC for the "Do You Know Your Targets" Quiz show where Dr. Natasha Leighl will go head to head against Dr. Ben Solomon! I'll play host and take a few crowd volunteers to play along for some prizes! IASLC Ben Solomon

Join me for a discussion on antibody drug conjugates in lung cancer - what role will ADCs play in the future? Free PeerView #CME panel on Monday September 9th, 12:15pm, Ballroom 20A (Upper Level) - with Drs. Melissa L. Johnson d.planchard and me! Info below: lrn.peerview.com/150209524_1/15…

#WCLC24 kicks off September 7 with nearly 20 workshops for a wide range of specialties and interests. Learn more in #ILCN: bit.ly/4g4u6O3 #LCSM

T-1.5 days until IASLC #WCLC24 And here are your Social Media Ambassadors- the IASLC communications committee🔊 Follow these folks to track the best in thoracic onc in San Diego☀️ Matthew Smeltzer Stephen V Liu, MD Charu Aggarwal, MD, MPH, FASCO Aakash Desai, MD, MPH Dusty Joy Donaldson Narjust Florez, MD, FASCO RadOncResearch

On our way to #WCLC24 ⁦Stephen V Liu, MD⁩ hoping that the flight delay will be resolved soon.

Our social media ambassadors for #WCLC24 Make sure to follow their updates and insights during the conference

Second primary lung cancer among patients with a history of breast cancer is strongly associated with smoking, in report Clinical Lung Cancer. 24% increased risk for every 10 smoking pack years. But most would not be eligible for lung cancer screening. clinical-lung-cancer.com/article/S1525-…